This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research article
Bing-He Xu
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Corresponding Author
ORCiD: https://orcid.org/0000-0002-0234-2747
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: The incidence and survival of breast cancer lung metastases (BCLM) patients at initial diagnosis of metastatic breast cancer (MBC) remain poorly identified in China.
Methods: We attained clinical data of 3161 MBC patients initially diagnosed between December 1991 and September 2019 from the China National Cancer Center and finally included 2263 MBC patients in this study, among which 809 patients presented with lung metastases at first MBC diagnosis. The risk factors for BCLM were determined using multivariate logistic regression analysis and the prognostic factors of BCLM patients were assessed by univariate and multivariate Cox regression analyses.
Results: Patients with triple-negative subtype (42.3%) harbored the highest incidence proportions of lung metastases. Age ≥ 50 years, ECOG 2 and triple-negative subtype were remarkably associated with higher incidence of lung metastases, while N3, liver and bone metastases were significantly correlated with lower odds of lung metastases at diagnosis. The median survival of BCLM patients was 41.7 months, with triple-negative subtype experiencing the worst prognosis of 26.8 months. ECOG 2, N3, HR-/HER2+ subtype, triple-negative subtype, liver metastases and bone metastases were significantly correlated with poor survival of BCLM patients.
Conclusions: Our study provides essential information on clinicopathological features, incidence and survival outcomes of BCLM patients at initial diagnosis of MBC in China.
Keywords
Incidence, survival, prognosis, metastatic breast cancer, lung metastases
Figure 1
Figure 2
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 03 Mar, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cancer Biology
Learn more about our company.
This is a preprint. It has not completed peer review.
Research article
Bing-He Xu
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Corresponding Author
ORCiD: https://orcid.org/0000-0002-0234-2747
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 03 Mar, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cancer Biology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: The incidence and survival of breast cancer lung metastases (BCLM) patients at initial diagnosis of metastatic breast cancer (MBC) remain poorly identified in China.
Methods: We attained clinical data of 3161 MBC patients initially diagnosed between December 1991 and September 2019 from the China National Cancer Center and finally included 2263 MBC patients in this study, among which 809 patients presented with lung metastases at first MBC diagnosis. The risk factors for BCLM were determined using multivariate logistic regression analysis and the prognostic factors of BCLM patients were assessed by univariate and multivariate Cox regression analyses.
Results: Patients with triple-negative subtype (42.3%) harbored the highest incidence proportions of lung metastases. Age ≥ 50 years, ECOG 2 and triple-negative subtype were remarkably associated with higher incidence of lung metastases, while N3, liver and bone metastases were significantly correlated with lower odds of lung metastases at diagnosis. The median survival of BCLM patients was 41.7 months, with triple-negative subtype experiencing the worst prognosis of 26.8 months. ECOG 2, N3, HR-/HER2+ subtype, triple-negative subtype, liver metastases and bone metastases were significantly correlated with poor survival of BCLM patients.
Conclusions: Our study provides essential information on clinicopathological features, incidence and survival outcomes of BCLM patients at initial diagnosis of MBC in China.
Figure 1
Figure 2
Loading...